8-K: Regenerex Pharma CFO Terminated for Cause

Regenerex Pharma, Inc. announced the termination of Chief Financial Officer Kenneth Perry for Cause, effective May 2, 2026, following a review of his conduct.

Summary

• Regenerex Pharma, Inc. has terminated its Chief Financial Officer, Kenneth Perry, for Cause.
• The termination follows a determination by the Board of Directors, based on a recommendation from the Governance and Nominating Committee, that Mr. Perry's conduct constituted a material and continuing breach of his Employment Agreement.
• The Committee's review included audit-related findings, Board records, and documented communications.
• Mr. Perry was placed on administrative suspension with pay effective March 31, 2026.
• Notice of termination was delivered on May 2, 2026.
• Don E. Ray has been appointed as Interim Chief Financial Officer for an initial term of 90 days, effective April 1, 2026.
• The CEO recused himself from all deliberations and decisions regarding this matter.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the termination of a key executive for cause, which raises concerns about internal governance and potential financial irregularities.

Positives

• The company has taken decisive action to address potential misconduct by a key executive.
• The Board of Directors and its independent committee conducted a thorough review before making a decision.
• An interim CFO has been appointed to ensure continuity in financial operations.

Negatives

• The termination of a CFO for Cause indicates significant internal issues and potential governance concerns.
• The company is facing a leadership vacuum in its finance department, albeit temporarily.
• The mention of 'audit-related findings' suggests potential financial irregularities or control weaknesses.

Risks

• Potential for further investigation into audit-related findings.
• Disruption to financial operations and strategic planning due to CFO transition.
• Negative impact on investor confidence due to the nature of the termination.
• Potential for legal challenges from the former CFO.

Future Outlook

No specific future outlook or guidance is provided in this filing, which solely concerns the departure of the CFO.

Management Comments

• The Board of Directors, acting upon the recommendation of its Governance and Nominating Committee, determined that the conduct of the Company's Chief Financial Officer, Kenneth Perry, constituted a material and continuing breach of his Employment Agreement and satisfied the definition of Cause as set forth therein.
• The Committee conducted a comprehensive review of relevant materials, including audit-related findings, Board records, and documented communications.

Industry Context

StockSavvy.ai notes that CFO terminations for cause, especially when linked to audit findings, can signal underlying financial control weaknesses or governance issues, which are critical concerns for investors in the pharmaceutical sector where transparency and compliance are paramount.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to governance concerns and uncertainty.
• Employees: May experience uncertainty regarding financial leadership and company stability.
• Creditors/Suppliers: May seek reassurance regarding the company's financial management and stability.

Next Steps

• Continued search for a permanent Chief Financial Officer.
• Potential follow-up actions related to the 'audit-related findings'.

Key Dates

Recommendation

The termination of the CFO for cause introduces significant uncertainty and potential governance issues. While the company is taking action, the underlying reasons (audit findings) are concerning. A 'hold' recommendation is appropriate pending further clarity on the financial situation and the appointment of a permanent CFO.

Keywords

Regenerex Pharma, CFO Termination, Kenneth Perry, Cause for Termination, Interim CFO, Don E. Ray, Board of Directors, Governance